Decoding the targets of brain regulatory T cells
In plain English
AI plain-English summaryThe brain’s own anti-inflammatory immune cells—regulatory T cells, or Tregs—are potent drivers of tissue repair, but no one knows exactly what they are targeting. This matters because brain Tregs could be harnessed to treat conditions like multiple sclerosis, stroke, or neurodegeneration, yet their therapeutic potential remains locked. The key missing piece is the identity of the antigens—the molecular targets—that these cells recognise. Without that knowledge, researchers cannot design therapies that selectively activate or expand the protective Treg population. The team has developed scalable methods to identify the entire repertoire of antigens recognised by the brain’s Tregs in mice—a population so small it was previously out of reach. They will then validate the most promising targets in human patients using cerebrospinal fluid samples. If successful, this work would unlock the first complete map of brain Treg targets, enabling precise immune therapies that boost repair without triggering harmful inflammation. It would also provide a blueprint for decoding T cell targets in other tissues, advancing the broader field of antigen discovery.
View original technical description
View the original record at the funder ↗
Researchers
Related Research
Grants with similar aims, by meaning.
Original classification
Discovery AwardPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know